» Articles » PMID: 38028470

Long-term Cardiovascular Mortality Risk in Patients with Bladder Cancer: a Real-world Retrospective Study of 129,765 Cases Based on the SEER Database

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Among 28 cancer types, bladder cancer (BC) patients have the highest risk of dying from cardiovascular disease (CVD). We aimed to identify the independent risk factors and develop a novel nomogram for predicting long-term cardiovascular mortality in patients with BC.

Methods: We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database for patients diagnosed with bladder cancer (BC) between 2000 and 2017. The cumulative incidence function (CIF) was computed for both CVD-related death and other causes of death. Then we performed univariate and multivariate analyses to explore the independent risk factors and further develop a novel nomogram to predict cardiovascular mortality at 5- and 10-year for patients with BC by using the Fine-Gray competing risk model. The efficacy of the developed nomogram was assessed by the concordance index (C-index), receiver operating characteristic (ROC) curve, calibration curve, and decision curve analysis (DCA).

Results: A total of 12,9765 patients were randomly divided into training ( = 90,835, 70%), and validation ( = 38,930, 30%) cohorts. During the follow-up period, 31,862 (46.4%) patients died from BC, and 36793 (53.6%) patients died from non-BC, of which CVD-related death accounted for 17,165 (46.7%), being the major cause of non-cancer deaths. The multivariate analysis showed that age, sex, race, marital status, histologic type, tumor grade, summary stage, and chemotherapy were independent risk factors of CVD-related death in BC patients. The nomogram based on the above eight factors showed good discrimination power, excellent consistency, and clinical practicability: (1) the areas under the curve of the ROC for 5- and 10-year CVD-related death of 0.725 and 0.732 in the training cohort and 0.726 and 0.734 in the validation cohort; (2) the calibration curves showed that the prediction probabilities were basically consistent with the observed probabilities; (3) the DCA curves revealed that the nomogram had high positive net benefits.

Discussion: To our knowledge, this was the first study to identify the independent risk factors and develop a novel nomogram for predicting long-term cardiovascular mortality in patients with BC based on the competing risk model. Our results could help clinicians comprehensively and effectively manage the co-patient of BC and CVD, thereby reducing the risk of cardiovascular mortality in BC survivors.

Citing Articles

Navigating the obesity paradox in bladder cancer prognosis-insights from the Taiwan National Health Insurance System Database.

Tseng W, Chiang T, Ho C, Huang S, Chiu A, Li C Front Nutr. 2024; 11:1433632.

PMID: 39723162 PMC: 11669321. DOI: 10.3389/fnut.2024.1433632.


Big Data, Big Insights: Leveraging Data Analytics to Unravel Cardiovascular Exposome Complexities.

Ibrahim R, Pham H, Nasir K, Hahad O, Sabharwal A, Al-Kindi S Methodist Debakey Cardiovasc J. 2024; 20(5):111-123.

PMID: 39525379 PMC: 11546329. DOI: 10.14797/mdcvj.1467.


Nomogram for predicting cardiovascular mortality in patients with gastrointestinal stromal tumor: A population-based study.

Wang H, Zheng K, Tai C, Sun Y, Feng S, Zhang Y Medicine (Baltimore). 2024; 103(39):e39835.

PMID: 39331912 PMC: 11441931. DOI: 10.1097/MD.0000000000039835.


Incidence of cardiovascular mortality among head and neck cancer patients.

Cao L, Wang Y, Wang S, Yu B, Fan J Eur Arch Otorhinolaryngol. 2024; 281(8):4351-4361.

PMID: 38724856 DOI: 10.1007/s00405-024-08670-5.

References
1.
Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L . Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2006; 66(6 Suppl 1):4-34. DOI: 10.1016/j.urology.2005.07.062. View

2.
Danforth K, Luong T, Yi D, Yamamoto A, Kawatkar A, Kim P . Disparities in Stage at Diagnosis in an Equal-access Integrated Delivery System: A Retrospective Cohort Study of 7244 Patients With Bladder Cancer. Clin Genitourin Cancer. 2020; 18(2):e91-e102. DOI: 10.1016/j.clgc.2019.09.002. View

3.
Quagliariello V, De Laurentiis M, Cocco S, Rea G, Bonelli A, Caronna A . NLRP3 as Putative Marker of Ipilimumab-Induced Cardiotoxicity in the Presence of Hyperglycemia in Estrogen-Responsive and Triple-Negative Breast Cancer Cells. Int J Mol Sci. 2020; 21(20). PMC: 7589802. DOI: 10.3390/ijms21207802. View

4.
Stoltzfus K, Zhang Y, Sturgeon K, Sinoway L, Trifiletti D, Chinchilli V . Fatal heart disease among cancer patients. Nat Commun. 2020; 11(1):2011. PMC: 7181822. DOI: 10.1038/s41467-020-15639-5. View

5.
Ghaferi A, Schwartz T, Pawlik T . STROBE Reporting Guidelines for Observational Studies. JAMA Surg. 2021; 156(6):577-578. DOI: 10.1001/jamasurg.2021.0528. View